On Tuesday, June 6, 2017, this letter was sent to the members of the House Energy and Commerce Committee opposing any amendments that may be offered to H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, that would allow the importation of foreign pharmaceuticals into the United States or that would undermine the preemptive authority of federal food and drug regulations. The Committee will mark up the bill tomorrow morning.
June 6, 2017
Dear Chairman Walden and Ranking Member Pallone:
Read more
On May 26, 2017, the Chamber sent this letter to the full United States Congress regarding the fiduciary rule and the Chamber’s recently released report, The Data is In: The Fiduciary Rule Will Harm Small Retirement Saver.
May 26, 2017
TO THE MEMBERS OF THE UNITED STATES CONGRESS:
Read more
This is a letter from U.S. Chamber of Commerce Senior Vice President & Chief Policy Officer Neil Bradley in response to Chairman Labrador and Vice-Chairman Johnson’s request to the Chamber for insight in identifying federal regulations and government processes, within the Committee’s jurisdiction, that are in need of reform as well as suggestions for reform.
Read more
On May 23, 2017, the U.S. Chamber of Commerce sent this letter to Senate Finance Committee Chairman Orrin Hatch that outlined several legislative reform recommendations as the Senate moves forward with crafting their own proposal for the repeal and replacement of Obamacare.
Read more
On Friday, May 19, the Chamber, along with 7 other trade associations representing insurers, hospitals, physicians and employers, sent a letter to U.S. Department of Health and Human Services Secretary Tom Price. The letter outlines serious concerns about the continued uncertainty around funding for cost-sharing reduction (CSR) payments and the negative impacts uncertainty will have on millions of Americans if it is not addressed.
Read more
On Friday, May 19, the Chamber, along with 7 additional trade associations representing insurers, hospitals, physicians and employers, sent a letter to Office of Management and Budget Director Mick Mulvaney. The letter outlines serious concerns about the continued uncertainty around funding for cost-sharing reduction (CSR) payments and the negative impacts uncertainty will have on millions of Americans if it is not addressed.
Read more
This letter was sent to Chairman Brady and the members of the Committee on Ways and Means expressing the Chamber’s commitment to comprehensive tax reform.
Read more
This letter was sent to the members of the House Subcommittee on Health opposing any amendments that may be offered to the Food and Drug Administration Reauthorization Act of 2017 that would allow the importation of foreign pharmaceuticals into the United States or that would undermine the preemptive authority of federal food and drug regulations. The Subcommittee is marking up the bill tomorrow morning.
May 17, 2017
Read more